

28 Nov 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J's pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna's co-founder shares tips on innovation.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 November 2021, including: the prospects and plans for [*Johnson & Johnson*](#)'s pharma and oncology business; China looks more inward under new policies; an important US approval for [*Takeda Pharmaceutical Co. Ltd.*](#); and [*Moderna, Inc.*](#)'s co-founder shares tips on innovation.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*No Way To Go But Grow: J&J Outlines Plans To Become A \\$60bn Pharma In 2025*](#)" - Scrip, 18 Nov, 2021.)

(Also see "[*Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology*](#)" - Scrip, 18 Nov, 2021.)

(Also see "[*Pharma Will Need To Embrace More Inward-Looking China*](#)" - Scrip, 24 Nov, 2021.)

(Also see "[*Takeda's Livtency Approved For Refractory CMV Infection In Transplant Patients*](#)" - Scrip, 25 Nov, 2021.)

(Also see "[*Moderna Co-Founder Robert Langer's Tips For Innovation*](#)" - Scrip, 22 Nov, 2021.)

[*Click here to explore this interactive content online*](#) ✎